+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Lung Cancer Genomic Testing Market by Technology, Test Type, Application, End User - Global Forecast to 2030- Product Image
Lung Cancer Genomic Testing Market by Technology, Test Type, Application, End User - Global Forecast to 2030- Product Image
Sale

Lung Cancer Genomic Testing Market by Technology, Test Type, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 181 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5925112
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Advancements in lung cancer genomic testing are redefining personalized oncology, supporting more precise diagnostics and therapy decisions. As demand for targeted treatment grows, leaders in healthcare and biotechnology must evaluate key trends shaping this dynamic landscape.

Market Snapshot: Lung Cancer Genomic Testing Market

The Lung Cancer Genomic Testing Market is advancing rapidly, with a revenue trajectory from USD 1.07 billion in 2024 to USD 1.16 billion in 2025. A projected CAGR of 8.35% positions the market to reach USD 1.73 billion by 2030. This robust expansion highlights the increasing integration of molecular diagnostics, as oncologists and laboratories seek fast, actionable insights for improving patient management and outcomes.

Scope & Segmentation

  • Technologies: Fluorescence in situ hybridization, microarray, next generation sequencing (targeted, whole exome, whole genome sequencing), real time polymerase chain reaction, and Sanger sequencing.
  • Test Types: Liquid biopsy (circulating tumor cells, circulating tumor DNA) and tissue biopsy (fine needle aspiration, tissue section).
  • Applications: Companion diagnostics, predictive testing, prognostic testing, and treatment monitoring.
  • End Users: Academic and research institutes, hospitals and diagnostic laboratories, pharmaceutical and biotechnology companies.
  • Regional Coverage: Americas (United States: California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio; Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan).
  • Key Companies: Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche AG, QIAGEN N.V., Guardant Health, Inc., Myriad Genetics, Inc., Natera, Inc., BioMérieux S.A., NeoGenomics Laboratories, Inc., Foundation Medicine, Inc.

Key Takeaways for Decision-Makers

  • Genomic testing technologies continue to evolve, driving greater test accuracy and supporting the shift toward precision oncology across varied clinical settings.
  • Liquid biopsy uptake is accelerating, favored for its less invasive approach and real-time monitoring capabilities that enhance patient management and clinical workflows.
  • Cross-sector collaboration between diagnostic developers, hospitals, and biopharma is fostering the co-development of assays, driving faster bench-to-bedside translation.
  • Ecosystem players are prioritizing automation and digital solutions to address rising sample volumes and the increasing need for rapid, high-sensitivity analyses.
  • AI and machine learning applications are emerging in bioinformatics, offering tools for predictive analytics and deeper insights from complex genomic datasets.
  • Regional regulatory efforts and national genomics strategies are enabling broader adoption, especially in emerging markets pursuing expansion of cancer diagnostic capacity.

Tariff Impact: U.S. Regulatory Shifts

In 2025, new tariffs in the United States on imported genomic reagents, sequencing instruments, and diagnostic supplies are affecting operational expenses and supply strategies. Increased costs for essential components, especially for next generation sequencing, have prompted laboratories to invest in domestic partnerships and pursue alternative sourcing models. These tariffs reinforce the need for supply chain resilience, with industry dialogue now focusing on local production and strategic sourcing to ensure consistent access to critical materials for genomic testing.

Methodology & Data Sources

This market intelligence is rooted in comprehensive primary research, including interviews with over 50 clinical and industry experts, and is supported by secondary analysis of scientific literature, regulatory documents, and proprietary databases. Triangulation of supply and demand data, coupled with expert committee validation, ensures robust and clinically relevant market insights.

SEO Focus: Lung Cancer Genomic Testing Market

The lung cancer genomic testing market is at a pivotal stage, with precision medicine reshaping diagnostic pathways for oncology. Innovation in next generation sequencing, adoption of liquid biopsies, and advancements in companion diagnostics are transforming clinical practice. Decision-makers must stay ahead of new regulatory developments and technological shifts to leverage growth opportunities in both established and emerging geographies.

Why This Report Matters

  • Supports strategic planning by delivering actionable intelligence on the competitive, regulatory, and technological landscape.
  • Guides investments in platforms and partnerships to enhance portfolio resilience and address evolving care pathways in oncology.
  • Enables payers, providers, and industry stakeholders to benchmark and anticipate shifts in test adoption, reimbursement, and supply chain management.

Conclusion

Lung cancer genomic testing is reshaping clinical decision-making and market strategies for diagnostics and therapeutics. This report provides a clear view of critical trends, empowering stakeholders to navigate change and unlock value.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Lung Cancer Genomic Testing Market, by Technology
8.1. Introduction
8.2. Fluorescence in Situ Hybridization
8.3. Microarray
8.4. Next Generation Sequencing
8.4.1. Targeted Sequencing
8.4.2. Whole Exome Sequencing
8.4.3. Whole Genome Sequencing
8.5. Real Time Polymerase Chain Reaction
8.6. Sanger Sequencing
9. Lung Cancer Genomic Testing Market, by Test Type
9.1. Introduction
9.2. Liquid Biopsy
9.2.1. Circulating Tumor Cells
9.2.2. Circulating Tumor Dna
9.3. Tissue Biopsy
9.3.1. Fine Needle Aspiration
9.3.2. Tissue Section
10. Lung Cancer Genomic Testing Market, by Application
10.1. Introduction
10.2. Companion Diagnostics
10.3. Predictive Testing
10.4. Prognostic Testing
10.5. Treatment Monitoring
11. Lung Cancer Genomic Testing Market, by End User
11.1. Introduction
11.2. Academic and Research Institutes
11.3. Hospitals and Diagnostic Laboratories
11.4. Pharmaceutical and Biotechnology Companies
12. Americas Lung Cancer Genomic Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Lung Cancer Genomic Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Lung Cancer Genomic Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Illumina, Inc.
15.3.2. Thermo Fisher Scientific Inc.
15.3.3. F. Hoffmann-La Roche AG
15.3.4. QIAGEN N.V.
15.3.5. Guardant Health, Inc.
15.3.6. Myriad Genetics, Inc.
15.3.7. Natera, Inc.
15.3.8. BioMérieux S.A.
15.3.9. NeoGenomics Laboratories, Inc.
15.3.10. Foundation Medicine, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. LUNG CANCER GENOMIC TESTING MARKET MULTI-CURRENCY
FIGURE 2. LUNG CANCER GENOMIC TESTING MARKET MULTI-LANGUAGE
FIGURE 3. LUNG CANCER GENOMIC TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. LUNG CANCER GENOMIC TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. LUNG CANCER GENOMIC TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. LUNG CANCER GENOMIC TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY REAL TIME POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE SECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PREDICTIVE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PROGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 50. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 51. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 52. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 53. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 54. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 55. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. CANADA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 57. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 58. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 59. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 61. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 62. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 63. MEXICO LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 69. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. BRAZIL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 91. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. UNITED KINGDOM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 95. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 97. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 98. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. GERMANY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 102. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 103. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 104. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 105. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. FRANCE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 112. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 113. RUSSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 116. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 117. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 118. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 119. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. ITALY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 121. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 122. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 123. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 124. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 125. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 126. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 127. SPAIN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 133. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. UNITED ARAB EMIRATES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 140. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. SAUDI ARABIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 147. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. SOUTH AFRICA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 151. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 152. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 153. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 154. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 161. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 164. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 165. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 166. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 167. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 168. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. QATAR LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 170. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 171. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 172. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 173. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 174. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 175. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 176. FINLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 182. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 183. SWEDEN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 189. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 190. NIGERIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 191. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 192. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 193. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 194. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 195. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 196. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. EGYPT LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 199. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 200. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 201. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 202. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 203. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. TURKEY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 210. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 211. ISRAEL LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 212. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 213. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 214. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 215. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 216. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 217. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 218. NORWAY LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 221. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 222. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 223. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 224. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. POLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 231. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 232. SWITZERLAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 239. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 240. ASIA-PACIFIC LUNG CANCER GENOMIC TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 241. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 243. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 244. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 245. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 246. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. CHINA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 249. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 250. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 251. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 252. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 253. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 254. INDIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 255. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 257. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 258. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 259. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 260. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. JAPAN LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 267. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 268. AUSTRALIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 274. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH KOREA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 283. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 285. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 286. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 287. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 288. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. THAILAND LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 295. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 296. PHILIPPINES LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 301. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 302. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. MALAYSIA LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 304. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 305. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 306. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 307. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 308. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 309. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 310. SINGAPORE LUNG CANCER GENOMIC TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 313. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 314. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY LIQUID BIOPSY, 2018-2030 (USD MILLION)
TABLE 315. VIETNAM LUNG CANCER GENOMIC TESTING MARKET SIZE, BY TISSUE BIOPSY, 2018-2030 (USD MILLION)
TABLE 316. VIETN

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Lung Cancer Genomic Testing market report include:
  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche AG
  • QIAGEN N.V.
  • Guardant Health, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • BioMérieux S.A.
  • NeoGenomics Laboratories, Inc.
  • Foundation Medicine, Inc.

Table Information

Report AttributeDetails
No. of Pages181
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 1.16 Billion
Forecasted Market Value ( USD ) by 2030 $ 1.73 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Genomic Cancer Panel and Profiling Markets 2025-2029 by Cancer, Application, Tissue, and Gene Type with Screening Potential Market Size, Featuring Executive & Consultant Guides - Product Image

Genomic Cancer Panel and Profiling Markets 2025-2029 by Cancer, Application, Tissue, and Gene Type with Screening Potential Market Size, Featuring Executive & Consultant Guides

  • Report
  • 585 Pages
  • Global
From
Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast to 2030 - Product Image

Cancer/Tumor Profiling Market by Technology, Product Type, Application, End User - Global Forecast to 2030

  • Report
  • 180 Pages
  • Global
From
Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Cancer Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Diagnostic - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033 - Product Image

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033

  • Report
  • 136 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.